{"id":"https://openalex.org/W2806079983","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.277","title":"Analysis of Cognitive Adverse Events in Two Phase III Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy Trials (P5.277)","display_name":"Analysis of Cognitive Adverse Events in Two Phase III Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy Trials (P5.277)","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2806079983","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.277","mag":"2806079983"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.90.15_supplement.p5.277","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.277","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.90.15_supplement.p5.277","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018402892","display_name":"Jay A. Salpekar","orcid":"https://orcid.org/0000-0002-6023-9430","observed_orcids":["https://orcid.org/0000-0002-6023-9430"]},"institutions":[{"id":"https://openalex.org/I1298154867","display_name":"Kennedy Krieger Institute","ror":"https://ror.org/05q6tgt32","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1298154867"]},{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Salpekar","raw_affiliation_strings":["Kennedy Krieger Institute, Johns Hopkins University, School of Medicine Baltimore MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kennedy Krieger Institute, Johns Hopkins University, School of Medicine Baltimore MD United States","institution_ids":["https://openalex.org/I1298154867","https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080677331","display_name":"Cynthia L. Harden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Harden","raw_affiliation_strings":["Mount Sinai Downtown - Union Square New York NY United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Sinai Downtown - Union Square New York NY United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088890091","display_name":"David W. Loring","orcid":"https://orcid.org/0000-0003-2497-1074","observed_orcids":["https://orcid.org/0000-0003-2497-1074"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Loring","raw_affiliation_strings":["Emory University Atlanta GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University Atlanta GA United States","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084941652","display_name":"Todd Grinnell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd Grinnell","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101974561","display_name":"David Cantu","orcid":"https://orcid.org/0000-0003-3174-0530","observed_orcids":["https://orcid.org/0000-0003-3174-0530"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Cantu","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014901271","display_name":"JungAh Jung","orcid":"https://orcid.org/0000-0002-2990-2070","observed_orcids":["https://orcid.org/0000-0002-2990-2070"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"JungAh Jung","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103238393","display_name":"David E. Blum","orcid":"https://orcid.org/0000-0002-1150-8331","observed_orcids":["https://orcid.org/0000-0002-1150-8331"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Blum","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1965,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.56156946,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"90","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.7813000082969666,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.7813000082969666,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.04479999840259552,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.01850000023841858,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eslicarbazepine-acetate","display_name":"eslicarbazepine acetate","score":0.9980000257492065},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.9919999837875366},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.5199999809265137},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.8809999823570251},{"id":"https://openalex.org/keywords/cognitive-safety","display_name":"cognitive safety","score":0.3310000002384186}],"concepts":[{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6965847611427307},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5056228637695312},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.43751251697540283},{"id":"https://openalex.org/C3017906399","wikidata":"https://www.wikidata.org/wiki/Q48973845","display_name":"Pooled analysis","level":3,"score":0.4236370921134949},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4131961762905121},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37862175703048706},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.19920223951339722},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.04760989546775818}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.90.15_supplement.p5.277","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.277","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.90.15_supplement.p5.277","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7799999713897705,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2806568072","https://openalex.org/W2317472975","https://openalex.org/W2805579729","https://openalex.org/W2794846120","https://openalex.org/W4389445225","https://openalex.org/W4389449912","https://openalex.org/W4288968146","https://openalex.org/W1534295045","https://openalex.org/W2590296308","https://openalex.org/W2762492465"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"examine":[2],"the":[3,135,195,201,211,295],"frequency":[4],"of":[5,38,170,204,297],"cognitive":[6,171,199,213,227,236,259,271,298],"treatment-emergent":[7],"adverse":[8,130],"events":[9,131],"(TEAEs)":[10],"in":[11,36,46,66,192,232,242,251,254,282,302,351],"two":[12,55],"conversion-to-ESL":[13,47,60,285],"monotherapy":[14,48,61,286],"trials.":[15,49],"Background:":[16],"ESL":[17,87,119,165,181,222,246],"is":[18],"a":[19,270,335,378,401,424,447],"once-daily":[20],"oral":[21],"antiepileptic":[22],"drug":[23],"(AED)":[24],"for":[25,95,123,138,331,355,374,397,420,443],"partial-onset":[26],"(focal)":[27],"seizures":[28],"(POS).":[29],"Cognition-related":[30],"TEAEs":[31,127,172,228,237,279,299],"(cognitive":[32],"TEAEs)":[33],"were":[34,52,83,142,150,194,230,238,261,280,289,300],"infrequent":[35,281],"trials":[37,62],"adjunctive":[39],"ESL,":[40],"but":[41],"have":[42],"not":[43,145],"been":[44],"evaluated":[45],"Design/Methods:":[50],"Data":[51],"pooled":[53,109],"from":[54,317,366],"Phase":[56,283],"III":[57,284],"randomized,":[58],"dose-blind,":[59],"(093-045":[63],"and":[64,128,190,294,357],"-046)":[65],"adults":[67],"(16\u201370":[68],"years)":[69],"with":[70,343,386,409,432,455],"POS":[71],"uncontrolled":[72],"by":[73],"1\u20132":[74],"AEDs.":[75],"Following":[76],"an":[77,352],"8-week":[78],"baseline":[79,103,217],"period,":[80],"eligible":[81],"patients":[82,115,160],"randomized":[84,114],"2:1":[85],"to":[86,275,323],"1600":[88,162,178,219,247,266],"mg":[89,92],"or":[90,340,383,406,429,452],"1200":[91,166,182,223],"once":[93],"daily":[94],"18":[96],"weeks":[97,99,102,106],"(2":[98],"titration,":[100],"6":[101],"AED-taper,":[104],"10":[105],"monotherapy).":[107],"The":[108,155],"intent-to-treat":[110],"(ITT)":[111],"population":[112,157],"(all":[113],"who":[116],"received":[117,314,328,348,363,371,394,417,440],"\u22651":[118],"dose)":[120],"was":[121,173,206,210],"used":[122],"all":[124],"analyses.":[125],"Cognitive":[126,278],"serious":[129],"(SAEs)":[132],"(categorized":[133],"using":[134],"Medical":[136],"Dictionary":[137],"Regulatory":[139],"Activities,":[140],"v13.1)":[141],"identified.":[143],"Terms":[144],"typically":[146],"regarded":[147],"as":[148],"cognition-related":[149],"included":[151],"(FDA":[152],"request).":[153],"Results:":[154],"ITT":[156],"comprised":[158],"365":[159],"(ESL":[161,177,218,265],"mg,":[163,167,179,183,220,224,267],"n=242;":[164],"n=123).":[168],"Incidence":[169],"similar":[174,290],"between":[175,291],"doses":[176],"7.0%;":[180],"7.3%).":[184],"Memory":[185],"impairment,":[186],"irritability,":[187],"skin":[188],"laceration,":[189],"disturbance":[191],"attention":[193],"most":[196],"frequently":[197],"reported":[198,215],"TEAEs;":[200],"overall":[202],"incidence":[203],"each":[205,255],"<2%.":[207],"Skin":[208],"laceration":[209],"only":[212],"TEAE":[214,272],"at":[216],"0.8%;":[221],"1.6%).":[225],"Most":[226],"(70.4%)":[229],"mild":[231,301],"severity.":[233,303],"Three":[234],"severe":[235,240,249],"reported:":[239],"amnesia":[241],"one":[243,252],"patient":[244,253,264],"taking":[245],"mg;":[248],"agitation":[250],"dose":[256,292],"group.":[257],"No":[258],"SAEs":[260],"reported.":[262],"One":[263],"0.4%)":[268],"had":[269],"(aggression)":[273],"leading":[274],"discontinuation.":[276],"Conclusions:":[277],"trials;":[287],"incidences":[288],"groups,":[293],"majority":[296],"Study":[304],"Supported":[305],"by:":[306],"Sunovion":[307,388,411,434,457],"Pharmaceuticals":[308,389,412,435,458],"Inc.":[309,390,413,436,459],"Disclosure:":[310],"Dr.":[311,325,345,360,368,391,414,437],"Salpekar":[312],"has":[313,321,327,347,362,370,393,416,439],"research":[315,364],"support":[316,365],"Lundbeck.":[318],"Dr":[319],"Harden":[320],"nothing":[322],"disclose.":[324],"Loring":[326,346,361],"personal":[329,349,372,395,418,441],"compensation":[330,350,373,396,419,442],"consulting,":[332,375,398,421,444],"serving":[333,376,399,422,445],"on":[334,377,400,423,446],"scientific":[336,379,402,425,448],"advisory":[337,380,403,426,449],"board,":[338,381,404,427,450],"speaking,":[339,382,405,428,451],"other":[341,384,407,430,453],"activities":[342,385,408,431,454],"NeuroPace.":[344],"editorial":[353],"capacity":[354],"Epilepsia":[356],"Neuropsychology":[358],"Review.":[359],"Medtronic.":[367],"Grinnell":[369],"Employment:":[387,410,433,456],"Cantu":[392],"Jung":[415],"Blum":[438]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2018-06-13T00:00:00"}